Monday, September 17, 2012

Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Hemophilia

Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia:
LONDON and MOSCOW, September 11, 2012 /PRNewswire/ –

Original article can be found here.
Subcutaneous blood factors expected to revolutionise the treatment paradigm of haemophiliac patients worldwide
Pro Bono Bio Group plc (“PBB”), the international healthcare group, announces the successful conclusion of a series of pre-clinical trials in haemophiliac subjects conducted with the world’s first long acting blood Factors VIIa, VIII and IX capable of subcutaneous administration. The results of these trials are of great importance as these novel long-acting, subcutaneous blood factors are expected to revolutionise the treatment paradigm for haemophilia sufferers worldwide. The availability of PBB’s subcutaneous blood factors would make self-administration by patients at home much easier leading to a significant improvement in treatment compliance and reduction in healthcare system costs by avoiding the need for regular IV infusions.
Key findings from the 8 trials with 6 products conducted at the University of Alabama were:
  • PBB’s current subcutaneous form of FVIIa achieved up to 3 days of haemostatic cover providing the prospect of sustained prophylactic treatment for haemophilia A patients who suffer an immune response to FVIII meaning that FVIII is no longer a viable therapy for them.
  • PBB’s current intravenous form of Factor VIIa achieved a 12x extension of haemostasis over current commercially available products. This means it could offer significant advantages in trauma applications in hospitals where haemostatic cover can be maintained for the duration of long operations and post-operation, without the current need for multiple administrations and related complications.
  • PBB’s subcutaneous form of Factor VIII for haemophilia A achieved a circulating dose level of 20% of the intravenous version and also maintained haemostasis for 72 hours, meaning that it is already suitable for twice-weekly dosing and will be able to be administered at higher subcutaneous doses enabling once weekly dosing or better.
  • PBB’s subcutaneous form of FIX for haemophilia B maintained haemostasis for 10 days meaning that it is already suitable for dosing less frequently than once per week.
  • PBB expects to optimise these products so that each one will provide haemostatic cover for at least a week and possibly two weeks from a single subcutaneous injection (with circulating blood factor maximum dose levels (“Cmax“) in line with the Malmo Protocol).

Following these successful trials PBB now has 6 blood factor products under development of which 3 can be administered subcutaneously and 3 by intravenous (“IV”) injection. Each of these blood factor products has proven efficacy in a sophisticated combination of in vivo trials in naturally haemophiliac subjects and in vitro assays. PBB’s novel improved blood factors utilise the epitope-cloaking property of PEG to prevent the products from being rapidly detected and destroyed by the patient’s own immune system before the product has had a chance to fulfil its therapeutic potential. This property has already been demonstrated by PBB in a haemophilia B dog. Work is underway to demonstrate that PBB’s other blood factor products are similarly “immune-silent”.
PBB intends to optimise these products, confident that effective prophylactic cover will now be possible with each of these blood factors via a once-a-week regimen of shallow subcutaneous injections.
Professor Ted Tuddenham, emeritus Professor of Haemophilia at University College London and former Director of the Haemophilia Centre at the Royal Free Hospital, a pioneer in the development of gene therapy treatments for haemophilia commented “I consider these products to be a vital breakthrough by PBB as the availability of subcutaneous and long acting blood factors will dramatically improve the quality of life and treatment regimes for haemophilia sufferers. There is a clear and present need for these products, which in the longer term, will continue to augment potential gene therapy options.”
John Mayo, CEO of PBB said, “This is great news.  These new, improved blood factors have the potential to revolutionise the quality of life for haemophilia sufferers. These new products also have huge commercial potential.  It is medically, morally and commercially important that these products get to market as quickly as possible.”
Further Information
Overview of PBB’s blood factor technology
PBB has been able to generate these improved blood factors that retain their efficacy and have a longer half life while being capable of subcutaneous administration by attaching an inert molecule of polyethylene glycol (“PEG”) to each individual blood factor molecule in a precise location remote from the active site on each blood factor. PBB’s technology has been applied and tested successfully on several recombinant and plasma sourced blood factor proteins.
  • PBB has enhanced the performance of blood factors by pioneering the PEGylation of these proteins with TheraPEG™ technology, developed independently by Polytherics Ltd.
  • The recombinant human protein molecules are conjugated to a polyethylene glycol (“PEG”) molecule. TheraPEG™ technology is uniquely successful where previous attempts to PEGylate blood factors have failed, by carefully locating PEG remotely from the active site on each protein, and by covering epitopes which otherwise trigger an immune response.
  • The careful individual pegylation of each molecule ensures that, molecule by molecule, the blood factors are made more water soluble.  This enables subcutaneous delivery and allows the products to be formulated with less polysorbate, reducing the total amount of polyethylene glycol administered to a patient (when compared to conventional prophylaxis).
  • PBB has substantial intellectual property around these products, including exclusive global licences to TheraPEG™ in relation to these blood factors, in addition to PBB’s own patents.

Summary observations from PBB’s blood factor trials
Subcutaneous delivery
PBB achieved a world first in correcting the whole-blood clotting times of naturally haemophilic dogs to normal via a low-volume subcutaneous injection. As expected, unmodified proteins that were administered subcutaneously in the same studies (and at equivalent dose levels) were ineffective in providing haemostatic cover.
Naked                             Expected PBB
              protein   PBB protein Extension of    Protein
     Blood  Haemostatic Haemostatic duration of   Haemostatic   Subcutaneous
    Factor   cover (i)   cover (i)  Haemostasis      Cover     Bioavailability
     FVIIa     0 hrs      72 hrs    --lemniscate   168+ hrs    89%
     FVIII     0 hrs      72 hrs    --lemniscate   168+ hrs    40% (ii)
      FIX      0 hrs      240 hrs   --lemniscate    336 hrs    86%
(i) The duration of “cover” is the time over which a whole blood clotting time of less than 12 minutes could be maintained
(ii) FVIII bioavailability figure reflects a minimum measurement (based on assays for the existing native protein) that is expected to improve as PBB develops specific assays for the new, improved protein.
Further extensions in duration of cover with the subcutaneous products are confidently expected since the Cmax of the subcutaneous products is significantly lower than for the intravenous products, providing plenty of scope for safe dose increases and further product optimisation.

Intravenous delivery
Long-acting intravenous products are ideal for trauma applications including surgical and post-surgical treatment. PBB’s modified blood factors clearly outperformed the currently available products (naked protein) in all trials.
Current PBB               Expected PBB
               Naked protein     protein    Extension of   Protein
      Blood     Haemostatic    Haemostatic  duration of  Haemostatic
     Factor      cover (i)      cover (i)   Haemostasis     Cover
      FVIIa        8 hrs          96hrs         12x        168 hrs
      FVIII        24 hrs         96 hrs         4x        168 hrs
       FIX         72 hrs        240 hrs         3x        336 hrs
(i) The duration of “cover” is the time over which a whole blood clotting time of less than 12 minutes could be maintained
PBB is confident that with regular product optimisation normal haemostatic cover of at least one week will be achieved for all 3 blood factors, both intravenously and subcutaneously.
These improved blood factors make possible, for the first-time, a subcutaneous, long-acting prophylactic regime that would lead to substantial improvements to the quality of life for haemophiliacs.  Ease of administration, easier home use and a more convenient dosing regimen will result in improved compliance, thereby reducing the occurrence of micro-bleeds into the joints (leading to premature joint degradation), avoidance of vascular damage by high-volume intravenous dosage and a smoother and more consistent plasma concentration profile, giving a better prediction of the therapeutic benefit of these factors over time, benefitting patients and caregivers alike.
Notes to Editors
About Pro Bono Bio Group plc
Pro Bono Bio Group plc (“PBB”) is an international healthcare company, which partners with leading scientists, eminent physicians and specialist service providers, to ensure we have access to the best talent available to develop products that target key unmet medical needs.  PBB’s approach is designed to create and bring to market important new therapies which will improve the lives of patients worldwide.
Pro Bono Bio launched its first medicine, FLEXISEQ™ for the treatment of pain associated with osteoarthritis in 2012 in Germany. Dermatology products, ROSSOSEQ and EXOSEQ, are scheduled to launch later this year.
About Haemophilia
Haemophilia A is the genetic disorder which causes an absence of the naturally occurring blood Factor VIII.  Protein replacement therapy can be prophylactic (75%+ of patients in Western markets) or in response to bleeding events (greater in developing markets).  The value of the global market for Factor VIII products in 2010 was circa $5bn.
Haemophilia B is the genetic disorder which causes an absence of the naturally occurring blood Factor IX.  Protein replacement therapy can be prophylactic (75%+ of patients in Western markets) or event-driven (greater in developing markets).  The value of the global market for Factor IX products in 2010 was circa $1bn.
Factor VIIa is needed as a substitute for Factor VIII when some (circa 30% of) haemophilia A patients develop an immune response to injected Factor VIII, thereby limiting its effectiveness.    It is also used for the acute treatment of bleeding associated with major trauma and in some surgical settings.  The value of the global FVIIa market in 2010 was estimated at circa $1.6bn.
For Media and Analyst Enquiries:    David Dible, Citigate Dewe Rogerson, +44-207-638-9571
SOURCE Pro Bono Bio

Thursday, May 17, 2012

Avoid Pain from an Injection by Looking Away

Avoid Pain from an Injection by Looking Away [Health]:
If you've ever received an injection of any kind you might have heard the advice of the doctor to look away so it won't hurt. As it turns out, new research published in the journal Pain provides evidence that looking away actually does decrease the amount of pain you feel. More »

Wednesday, February 8, 2012

New Address:

Hey everybody just wanted to shoot a quick update out.

Our new address is but don't worry, the old address will still work just fine! Also, give the new address a few days to work completely.

Stay tuned for more frequent updates.

As always, check out The Daily Bleeder by HemoWeb for daily news from around the bleeding disorder community.

Saturday, September 17, 2011

Tour de Light Rail Today!

Today I am doing the Tour de Light Rail Pub Crawl befitting the Hemophilia Association of Arizona. While getting ready to go out and be social and be active, what is my first thought?

To do my medicine. To Infuse. To do my factor. Whatever you want to call it, the chance of a bleed has to be the first thing on my mind when it comes to staying active. Even though it's not a prophylaxis day, I know I'm going to do a fair amount of walking today so I just infused before I'm set to head out for the Blood Brotherhood meeting at Macayo's before the pub crawl. If I didn't, I would regret it later.

This will be my first time going on the pub crawl and I'm really looking forward to it. It's a great way to raise money for the Hemophilia Association of Arizona. For nore information, visit the sites below.

See you there!

Wednesday, September 14, 2011

Virtual Walk for Hemophilia

If you could make a huge difference in a few minutes, would you do it??

We are asking for your help!
Just take a couple minutes and a few clicks to help us reach our goal and raise $15,000 to help make a huge difference for a child!!

As part of the Arizona Hemophilia Walk, Bayer is sponsoring the 2011 Bayer Virtual Walk for Hemophilia in an effort to help raise money and awareness for the bleeding disorder community. 

To win, we need the most people to sign in to participate on our team!With your participation, The Arizona Hemophilia Association will come out on top!! 

Here's how:
  • Simply logon to
  • The only information provided is your first name, last initial and email address
  • You can choose not to get any promotional materials
  • Join the Virtual Walk
  • Create your character, enter your name and email
  • Remember to select the Arizona Hemophilia Association as the Local Chapter in step 4!!

Thank you for supporting the Arizona Hemophilia Association!!

The Arizona Hemophilia Association is dedicated to enhancing the quality of life for those living with a chronic inherited bleeding disorder.  The funds raised will help to fund programs and services, such as Camp HONOR, a camp for kids living with a bleeding disorder and their siblings.  

For more information,
please contact our office at 602-955-3947. 
Related Posts Plugin for WordPress, Blogger...